Edwards Studies Gene Therapy Compound As Vessel For Peripheral Growth
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' legacy as a Baxter spin-off is allowing the cardiovascular firm to pursue clinical applications of a peripheral artery disease (PAD) gene therapy compound without integrating it with a device
You may also be interested in...
Edwards Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman
Early clinical data profiling Edwards/Sangamo's EW-A-401 gene therapy for intermittent claudication (leg pain) in patients at the National Institutes of Health are expected to appear in the Oct. 19 issue of Circulation
Edwards Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman
Early clinical data profiling Edwards/Sangamo's EW-A-401 gene therapy for intermittent claudication (leg pain) in patients at the National Institutes of Health are expected to appear in the Oct. 19 issue of Circulation
Edwards’ drug/device combo
Edwards Lifesciences will integrate the EW-A-401 peripheral artery disease therapy with a catheter delivery system upon completion of an investigational new drug trial to evaluate efficacy of the compound, the firm clarifies Sept. 7 (1"The Gray Sheet" Sept. 6, 2004, p. 13). The catheter, which will treat cardiac ischemia, marks the firm's first drug/device combo product...